Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2018
2020 |
| gptkbp:approvedBy |
gptkb:Japan
gptkb:United_States |
| gptkbp:ATCCode |
gptkb:G04BD15
|
| gptkbp:brand |
gptkb:Gemtesa
Beova |
| gptkbp:CASNumber |
1379753-27-9
|
| gptkbp:developer |
gptkb:Urovant_Sciences
gptkb:Kyorin_Pharmaceutical |
| gptkbp:eliminationHalfLife |
~70 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C26H28F2N4O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vibegron
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
beta-3 adrenergic receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
Not assigned
|
| gptkbp:PubChem_CID |
CHEMBL2103887
71244488 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache nasopharyngitis |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
overactive bladder
|
| gptkbp:bfsParent |
gptkb:ROIV
|
| gptkbp:bfsLayer |
6
|